20.500.12556/DiRROS-31288 Prve slovenske klinične smernice za zdravljenje zmerne do hude luskavice s plaki pri odraslih bolnikih First Slovenian clinical guidelines for the management of moderate-to-severe plaque psoriasis in adult patients Izhodišče in cilji: V zadnjih letih je odobritev novejših bioloških zdravil za obvladovanje zmerne do hude luskavice v plakih omogočila doseči višje cilje zdravljenja. Po drugi strani pa so te terapije povezane z bistveno višjimi stroški, kar ustvarja vse večji pritisk plačnikov zdravstvenih storitev, da bi zmanjšali skupne izdatke, zato vplivajo na prakso predpisovanja zdravil. Za podporo zdravnikom pri spopadanju s temi izzivi so se oblikovale prve slovenske smernice za obvladovanje zmerne do hude luskavice v plakih pri odraslih bolnikih. Njihov namen je zagotoviti na dokazih temelječe smernice, ki dermatovenerologom omogočajo, da v vsakem trenutku predpišejo terapijo, za katero menijo, da je najprimernejša za posameznega bolnika. Metode: Smernice so bile razvite z uporabo strukturiranega pristopa Delphi, ki temelji na soglasju. Združenje slovenskih dermatovenerologov je sklicalo in uradno odobrilo delovno skupino 6 slovenskih dermatovenerologov. Po pregledu obstoječih nacionalnih in mednarodnih smernic je skupina pripravila začetne izjave o priporočilih, ki so bile ponovno revidirane in izglasovane, dokler ni bilo doseženo 100-odstotno soglasje. Zaključene izjave so nato prejeli člani Združenja slovenskih dermatovenerologov, ki predpisujejo biološka zdravila za luskavico. In ti so o njih glasovali. Rezultati in zaključek: Rezultat tega procesa je bil trden, soglasno sprejeti sklop na dokazih temelječih priporočil za slovenske dermatovenerologe, ki zajemajo izbiro sistemskih terapij, uvedbo ter zaporedje posameznih bioloških zdravil, opredelitev zmerne do hude bolezni, določanje ciljev zdravljenja in določanje neuspeha zdravljenja. Background: In recent years, the approval of newer biological therapies for the management of moderate-to-severe plaque psoriasis has enabled the achievement of higher treatment goals. On the other hand, these therapies are associated with substantially higher costs, creating increasing pressure from healthcare payers to reduce overall expenditure and influencing prescribing practices. To support clinicians in navigating these challenges, the first Slovenian guidelines for the management of moderate-to-severe plaque psoriasis in adult patients have been developed. Their purpose is to provide evidence-based guidance that empowers dermatovenerologists to prescribe, at any given time, the therapy they consider most appropriate for the individual patient. Methods: The guidelines were developed using a structured, consensus-based Delphi approach. A working group of six Slovenian dermatovenereology specialists was convened and formally approved by the Association of Slovenian Dermatovenereologists. Following a review of existing national and international guidelines, the group drafted initial recommendation statements, which were iteratively revised and voted on until 100% consensus was reached. The finalized statements were subsequently distributed for voting to members of the Association of Slovenian Dermatovenereologists prescribing biological therapies for psoriasis. Results and conclusion: This process resulted in a robust, consensus-driven set of recommendations for Slovenian dermatovenerologists, providing evidence-based guidance on selecting systemic therapies, initiating and sequencing biological drugs, defining moderate-to-severe disease, establishing treatment goals, and determining treatment failure. klinične smernice luskavica biološka zdravila sistemska terapija zdravljenje clinical guidelines psoriasis biologic drugs systemic therapy treatment true false true Slovenski jezik Angleški jezik Neznano 2026-07-24 09:30:26 2026-07-24 09:30:26 2026-07-25 03:45:58 0000-00-00 00:00:00 2026 0 0 Nasl. z nasl. zaslona; Opis vira z dne 6. 7. 2026; str. D21-D30 no. 5/6 Vol. 95 2026 0000-00-00 Zaloznikova Objavljeno NiDoloceno 0000-00-00 0000-00-00 0000-00-00 615.5 1581-0224 10.6016/ZdravVestn.3713 283707139 RAZ_Suler_Baglama_Spela_2026.pdf RAZ_Suler_Baglama_Spela_2026.pdf 1 98BBF60AA96B8E58939A11B70A09DE8E 4024e88bf32c557cc09d675c956b71e79df6b5a42ed5ced96f3ed2b889ba76c2 af0c49cc-8731-11f1-812a-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=48353 https://vestnik.szd.si/index.php/ZdravVest/article/view/3713 1 8cb2d48f-8731-11f1-812a-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=48352 Univerzitetni klinični center Ljubljana 0 0 0